ArticleInvestigative ophthalmology & visual science2026
High-Density Lipoprotein Cholesterol Levels and Risk of Age-Related Macular Degeneration.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the association between high-density lipoprotein cholesterol (HDL-C) levels and incident age-related macular degeneration (AMD) in a large cohort. Methods: This retrospective cohort study used electronic health records from 70 U.S. healthcare organizations in the TriNetX network from 2005 to 2025. Adults with at least two HDL-C measurements obtained at least three months apart were classified as having high HDL-C (all values ≥60 mg/dL) or low HDL-C (all values ≤39 mg/dL). Groups were matched 1:1 on demographics, comorbidities, medications, laboratory values, and healthcare utilization. Follow-up began at the second qualifying HDL-C measurement and continued for up to 10 years. Incident nonexudative and exudative AMD were evaluated using Kaplan-Meier and Cox proportional hazards analyses, with robustness assessed through nested matching, subgroup and sensitivity analyses, and positive and negative control outcomes. Results: Over 1.29 million person-years of follow-up, high HDL-C was associated with increased risk of nonexudative AMD (hazard ratio [HR] = 1.53; 95% confidence interval [CI], 1.32-1.78) and exudative AMD (HR = 1.37; 95% CI, 1.09-1.73). For nonexudative AMD, risk was elevated across early (HR = 1.55; 95% CI, 1.26-1.91), intermediate (HR = 1.82; 95% CI, 1.42-2.33), and advanced atrophic (HR = 1.85; 95% CI, 1.16-2.97) stages. Associations for nonexudative AMD were robust across washout periods, follow-up intervals, mortality exclusion, and stepwise matching. Associations for exudative AMD were consistently positive but less stable. Control outcomes supported the specificity and internal validity of the findings. Conclusions: Higher HDL-C levels were associated with increased risk of incident nonexudative AMD and a weaker, less consistent association with exudative AMD. These findings suggest that sustained HDL-C levels may be relevant to AMD risk assessment and warrant further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.